Can a simple test spare breast cancer patients from chemo?
NCT ID NCT07379918
Summary
This study is following 1000 women with a common type of early breast cancer for 10 years. The goal is to gather real-world evidence on whether a genomic test called EndoPredict can accurately identify patients who have a low risk of their cancer returning. If the test proves reliable, it could help doctors safely recommend hormone therapy alone for these patients, allowing them to avoid unnecessary chemotherapy and its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint-Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.